Spero Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
GSK PLC has filed an Amendment No. 9 to its Schedule 13D, reporting a decrease in its beneficial ownership of Spero Therapeutics, Inc. common stock to 16.4% due to an increase in Spero's outstanding shares.